

various published and unpublished sources considered to be reliable, Demiurge Technologies AG neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential losses arising from its use. Thank you.

From: Idonae Lovetrue <idonae@demiurge.technology>
Date: Saturday, 28 March 2020 at 15:53
To: [REDACTED] (b) (6)
Subject: COVID-19 aetiology and treatment for critically ill patients:
irinotecan+etoposide

Dear Dr. Anthony S Fauci,

This is Idonae, CEO at Demiurge Technologies AG, a Swiss AI-biopharma company making accurate and rapid drug discoveries for diseases with limited available clinical data. We are committed to the non-profit dissemination of our COVID-19 discoveries to the public to facilitate the search for COVID-19 effective treatments.

SARS-CoV-2 is fundamentally different from all the other viruses that the world has hitherto known, so treatments must be rationally designed to avoid fueling the adaptive mutation and the latent infection of SARS-CoV-2.

Demiurge is the world's first company that has discovered the detailed aetiology of COVID-19 that consistently explains the clinical features of COVID-19 and the McA-based scientific rationale of the candidate treatments for COVID-19
(<https://www.preprints.org/manuscript/202003.0341/v1>).

(b) (4)

